Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) EVP Sells 1,200 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Neena Patil sold 1,200 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $240.94, for a total transaction of $289,128.00. Following the sale, the executive vice president directly owned 47,671 shares in the company, valued at approximately $11,485,850.74. The trade was a 2.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ traded up $0.07 during mid-day trading on Monday, hitting $245.87. 465,442 shares of the company traded hands, compared to its average volume of 951,054. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The stock has a 50-day moving average price of $249.37 and a two-hundred day moving average price of $224.08. Jazz Pharmaceuticals PLC has a 1 year low of $123.88 and a 1 year high of $266.38. The stock has a market cap of $15.96 billion, a price-to-earnings ratio of 16.96, a P/E/G ratio of 0.22 and a beta of 0.36.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47). The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The company’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($8.25) EPS. Equities analysts anticipate that Jazz Pharmaceuticals PLC will post 21.5 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Canaccord Genuity Group set a $300.00 target price on Jazz Pharmaceuticals in a research report on Wednesday, August 26th. Truist Financial increased their price objective on shares of Jazz Pharmaceuticals from $264.00 to $281.00 and gave the stock a “buy” rating in a research note on Wednesday, August 26th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Piper Sandler upped their target price on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Finally, Wells Fargo & Company increased their price target on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $286.72.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in JAZZ. Sequoia Financial Advisors LLC grew its stake in shares of Jazz Pharmaceuticals by 9.4% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 4,527 shares of the specialty pharmaceutical company’s stock valued at $1,091,000 after acquiring an additional 389 shares during the period. Tidal Investments LLC raised its stake in Jazz Pharmaceuticals by 8.3% during the 2nd quarter. Tidal Investments LLC now owns 21,028 shares of the specialty pharmaceutical company’s stock worth $5,067,000 after acquiring an additional 1,615 shares during the period. WINTON GROUP Ltd bought a new stake in Jazz Pharmaceuticals during the 2nd quarter worth approximately $386,000. Integrated Wealth Concepts LLC lifted its holdings in Jazz Pharmaceuticals by 27.2% during the second quarter. Integrated Wealth Concepts LLC now owns 1,762 shares of the specialty pharmaceutical company’s stock valued at $425,000 after purchasing an additional 377 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 15.7% during the second quarter. NewEdge Advisors LLC now owns 2,285 shares of the specialty pharmaceutical company’s stock valued at $551,000 after purchasing an additional 310 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for disorders in neuroscience and oncology. The company concentrates on conditions with significant unmet medical needs, including sleep disorders, epilepsy, rare diseases and certain cancers.

Its neuroscience portfolio includes Xywav and Xyrem, oxybate-based treatments for narcolepsy, with Xywav also indicated for idiopathic hypersomnia in adults. Jazz also markets Epidiolex in the United States, known as Epidyolex in some international markets, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.

In oncology, Jazz’s products include Rylaze, an asparaginase therapy used as part of treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca, used for certain patients with metastatic small cell lung cancer; and Vyxeos, a chemotherapy formulation for certain cases of newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.